4^th International Conference on
Nanomedicine and Nanotechnology

Paul Stannard has worked internationally in the US, Europe, Middle East and Asia and spoke at Davos 2019 about the next industrial revolution (Industry 4.0) and the impact on Smart Cities and how Nanoscale technologies will change the world in almost every area of life including sustainable healthcare, energy, food production, transport, infrastructure, AI and telecoms and communications.Chairman of The World Nano Foundation for the commercialisation of nanotechnology. Chairman of Trustees for World Science Aid and Chairman and Founder of Nano Media Group who are launching an investment funding programme where Nanotechnology research and IP can be potentially used as a tangible asset for funding and investment. He is also Chairman of Enabling Tech Capital based in London. He is a passionate advocate for Nanomedicine, Nano materials as well as other Nano enabled technologies which create significant global value and impact as well as sustainability for everyone.

Impact Investment Future for Nanotechnology

Professor Kanwar is the group leader and laboratory head of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research in School of Medicine, Faculty of Health at Deakin University. His earlier research (for nearly a decade in New Zealand) has focused on studying pathophysiology and devising new treatments mainly for cancer and chronic inflammatory diseases. Prof. Kanwar is currently working on nanotechnology/nanomedicine based protein/peptide, aptamers and his research approach employs monotherapy (gene therapy, immunotherapy) and combinational therapy with commercially available chemotherapeutic agents including LNA-aptamers (RNA/DNA), peptides and other biomolecules such as siRNA, miRNA, aptamers, proteins, siRNA, miRNA and their chimera (LNA-aptamer chimera with siRNA/miRNA delivery for targeting expression of survivin (the validated anti-cancer target), HIF-1 and apoptotic signalling molecules in cancer and chronic inflammation.

Cancer and chronic inflammatory diseases targeted nanomedicine based drug delivery siRNA, miRNA anti-sense targeted gene nanomedicine based technology to target cancer and inflammation. Drug discovery with anticancer targets for cancer cell survival, death, arrest and repair. Development of recombinant proteins and searching new immunomodulatory and anti-inflammatory bioactives, proteins and peptides for cancer and neuroprotection. Development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of colon and breast cancers. Development of oral and intravenous administration of nanocarriers to overcome the challenging concept of drug resistance in various cancers. Development of new generation safe, biodegradable, less toxic, disease targeted natural contrast materials for imaging. Novel nano-medicinal based vaccines and immunotherapy Micro-fluidics and Lab-on-a-Chip devices for delivery and diagnosis.

Alain L. Fymat is a medical-physical scientist and an educator who was educated at the Universities of Bordeaux and Paris-Sorbonne, France, and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine & Science. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. His current research interests lie at the interface between science and medicine (precision medicine, nanobiotechnology, nanomedicine, genetics/epigenetics/ecogenetics). He has extensively published (>> 300 scholarly publications) and lectured in several national and international academic, professional, governmental and industrial venues. He is a a Board member of several institutions, Editor of the Journals “Nanobiotechnology” and “Global Nanomedicine”, and Honored Editor of the Journals “Cancer Prevention and Current Research” and “Nanomedicine Research”.

Radiology, Medicine

Ph.D. Rangel-Vázquez is a researcher at PCC. She have served as a reviewer for several journals: Journal of Applied Polymer Science, Materials Letters, Carbohydrate Polymers, Journal Polymer Engineering & Science, Thermochimica Acta, Journal of Molecular Structure, Journal of Surface and Coatings Technology, Academic Journal of Agricultural Research, World Journal of Engineering and Physical Sciences (WJEPS), Annual Research & Review in Biology, Journal of Applied Physical Science International, Global Conference on Polymer and Composite Materials 2015 and International Journal of Nanomedicine. She have worked in the Organizing of International congress such as: 2016 Spring World Congress on Engineering and Technologies (SCET 2016) in the topic: 2016 Spring International Conference on Materials Sciences and Technologies (MST-S-China); 2nd Conference International of Surface and Interface on Materials (Thailand, 2016); The 2nd Int'l Conference on Biomaterials and Applications (ICBA 2017), Thailand; The 3rd Int'l Conference on Surface and Interface of Materials (SIM 2017), China. The 3rd Int'l Conference on Advanced Composite Materials (ACM 2017), Thailand. She is on the Editorial Board of several journals including Journal of Pharmaceutics & Drug Development, Material Science and Engineering with Advanced Research, Journal of Nanomedicine Research, Nanomedicine Research Journal, Chemistry Journal, BAOJ Pharmaceutical Sciences (Bioaccent), Independent Journal of Managment & Production (Brazil) and Global Journal of Nanomedicine. She is an Editor in Chief of BAOJ Pharmaceutical Sciences and the Journal of Pharmaceutics & Drug Development, respectively.

Nanotechnology applied to controlled drug delivery systems. In particular, skin and brain cancer, diabetes mellitus, antifungical, Design and preparation of oral solid (tablets and capsules) dosage forms, Analysis of drugs in pure forms, formulations and biological matrices, Bioadhesive drug delivery systems, especially hydrogels, polymers, biopolymers and IPNs, respectively.

Dr. Kouros Motamed, Ph.D. has been the Director of Drug Development at NantBioScience, Inc. since April 2016. Prior to that, he has served as VP of Strategic Alliances and Clinical Communications and VP of Clinical Development and Nanomedicine at Sorrento Therapeutics from 2013 to 2016. He has also served as a co-founder and CSO/CTO of Igdrasol, Inc. and Biomiga Diagnostics start-up companies from 2011-2013. Prior to that, Dr. Motamed served as the MOA and Molecular Biology Group Head at Celgene Corp. and Abraxis BioScience Inc. from 2007-2011. Dr. Motamed held an Assistant Professorship position in the Department of Pathology and Vascular Biology Center at Georgia Health Sciences University from 2002-2007. He has over 30 original publications in peer-reviewed journals, over 50 conference presentations and has 5 issued patents. He has served on the Editorial Board of Journal of Nanomaterials & Molecular Nanotechnology since 2013. Dr. Motamed received a B.S. degree in Biology from University of San Francisco and a Ph.D. degree from the University of California, Davis in Microbiology.

Drug Discovery,Development Angiogenesis,Tumorigenesis, Tumor Microenvironment Normalization Clinical Biomarker, Companion Diagnostic Development Point-of-Care Diagnostics Clinical Development of Personalized Nanomedicines in Solid Tumors

Paolo Ferruti took his degrees at the University of Pavia and then was summoned by Giulio Natta at the Polytechnic of Milan. In 1968, he worked with Melvin Calvin in Berkeley at the Lawrence Radiation Laboratory of the University of California. In 1976, he became Full Professor at the University of Naples and then commuted to Bologna, Brescia and finally Milan. He authored more than 400 papers and 50 patents. His main scientific interests regard functional polymers for technical and biotechnological applications. He is credited for the invention of polyamidoamines. According to Research Gates, to date he authored or co-authored 323 publications and received 5696 citations

Nanomaterials, Biomaterials, Polymer materials, Tissue engineering

Dr. Elsaied Mohamed Abdel Whahed Completed his Bsc and Msc at Alexandria University in 1984 and 1993. He recived Ph.D. in Physical chemistry (especially treatment of wastewater from heavy metals) Alexandria University, Egypt. He serve as a Teacher Assistant from 1985-1986 at Alexandria University. From 2002- 2007 he become a Sift manager chemistry in gas chromatography lab, Petrochemical company - Alexandria, Egypt.He become a Director of the department for the PVC analysis Supervision on the analysis of the final product, intermediate and row material. Currently he is Professor of physical chemistry Damanhur university. His main Training did at Egyptian petrochemical company in the aeria of Boiler treatment, The material balance, Environmental assessment of sites based oil and new projects, Rehabilitation, Administrative system for the environment, etc.

I would like to subject the using of nanotechnology in energy conservation which is an important topic for me in my site as a researcher and developer in the petrochemical industry, which requires more information technology in addition to the latest updates on using nanostructures, especially the use of nano-catalysts and the substitution of traditional catalysts which lead to a small production and many pollutants, unlike the use of nano-catalysts, which provide more energy used in the interaction, as well as reduce the amount of reactors and also reduce the amount of polluting material which effects of the environment. I hope also to stand on the latest nanotechnology methods used in the treatment of organic pollutants without the use of chemicals or additional energy affect the cost of the final product.

Dr. Farid Menaa (Bsc. BioEngineering ; Bsc. Biology and Physiology ; Msc. Genetics ; Master Gerontology/Geriatrics ; PhD Radiation Oncology/Gerontology (Paris, France, 2003) ; three international post-doctoral terms in Oncology, Dermatology, Stem cells, Hematology, Genomics ; MBA Entrepreneurship and MD candidate), is an experienced and skilled inter- and multi-disciplinary professional. During his career, Dr. Menaa followed complementary formations in Marine Biology (Caen, France), Pharmacy (Liege, Belgium), Biochemistry, Chemistry and Biophysics (California, USA), Business Development and Management (USA and Brazil). During his ongoing career, Dr. Menaa has mainly contributed to the identification and function of new human genes modulated by radiation ; Discovered a new signaling pathway after DNA damage ; Pointed out the link between the presence of stem cells, some of their genetic mutations, and the patient’s diagnosis and prognostic ; Identified genomic alterations in adult sickle cell anemia patients with stroke ; Developed new phytotherapeutic formulations against skin conditions ; Demonstrated the importance of various natural medicines in the prevention and/or treatment of diverse inflammatory-state and non-communicable diseases (NCDs) ; Contributed to the development and characterization of new nanomaterials ; Developped personalized translational medical strategies to diagnose and treat better and faster chronic pathologies. In 2009, Dr. Menaa was named Chief Scientific Officer (CSO) and R&D&I Executive Vice-Pressident (EVP) for Fluorotronics, Inc, CA, USA, the leading company in Fluorine-Carbon Spectroscopy. Dr. Menaa co-developped and applied this innovative green technology to Nanomedicine, Medicinal Chemistry, Nanotechnology, Oncology, Pharmaceutical and Life Sciences. Dr. Menaa is currently Chief Editor of Journal of Nanomedicine and Nanotechnology (http://www.omicsonline.org/editorialboard-nanomedicine-nanotechnology-open-access.php), among his other involvements for the advancement of Medicine, Sciences and Technology. Dr. Menaa is the member of the technical/scientific committee of a large number of international scientific events, in particular he successfully organized the “Target Meeting´s 1st World Nanomedicine and Nanobiotechnology Online Conference” (http://www.targetmeeting.com; 2013). Dr. Menaa is also member of several prestigious medical and scientific organizations (e.g. AACR, AAAS, ASCB, IRSCC, SPIE, RSC, ACS, ASH, ASHG, AAPS), and the editor, guest editor and reviewer of a large number of esteemed journals worldwide (>80 in Sciences , Medicine, Technology and Business Administration). Dr. Menaa has authored or co-authored more than 100 articles (including research and review articles, books, book chapters, textbooks, proceedings, pending patents) and has participated to over 200 scientific international events. Overall, the holistic concept of Dr. Menaa led him to contribute for various clinical and R&D&I projects at the interface of Oncology, Nutrition/Micronutrition, Aging/Anti-Aging, OMICS (mainly Genomics) and Nanotechnology, in order to prevent, implement early diagnosis, and develop efficient and safer therapeutic options, in particular to improve the outcome of cancer patients, stroke patients and delay the aging process while improving their life quality.

Nanomedicine,Nanobiotechnology,Nanotheranostics; Oncology, Gerontology, Dermatology, Stem Cells, Emerging Green Technologies, Personalized Medicine; Translational Medicine; Integrative Biomedicine; Innovation & Quality, Professorship, Entrepreneurship, Business Development/Management, Marketing.

Ziyad S. Haidar is an Associate Professor of Biomaterials and Tissue Engineering and the Scientific Director of the Centro de Investigación en Biología y Regeneración Oral (CIBRO), Centro de Investigación Biomédica (CIB), Facultad de Odontología, Universidad de los Andes in Santiago de Chile. Concurrently, Prof. Dr. Haidar is the Founder and Head of the Biomaterials, Pharmaceutical Delivery and Cranio-Maxillo-Facial Tissue Engineering Laboratory (BioMat'X) and Faculty member in the PhD program (BioMedicine) at the Facultad de Medicina, Universidad de los Andes in Santiago de Chile. Haidar is an oral and maxillofacial surgeon with a PhD in biomaterials and tissue engineering from McGill University, Montréal , Canada; and post-doctoral training at the Montréal Shriners Hospital, McGill University Health Center, Montréal , Canada. Before moving to Chile, he served as the Chair of Excellence in BioEngineering at the Université de Limoges, Limoges, France and was an Assistant Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA. Haidar has won several prestigious awards from the International Bone and Mineral Society, Society for Biomaterials, Canadian Biomaterial Society and Canadian/Lebanese Society of Plastic Surgeons, to name a few. He has more than 80 publications, conference proceedings, text-books and patents and is an editorial board member of several national and international scientific journals and periodicals.

Patient-oriented application of bionanotechnology; Biopolymers; Bioceramics and Drug delivery systems for the repair; Restoration and replacement of challenging craniofacial and orthopaedic defects.

Ching-An Peng started his academic career as an assistant professor at the University of Southern California in Chemical Engineering Department and later on promoted to associate professor with tenure. He then worked at the National Taiwan University as a full professor and at Michigan Technological University as the first holder of the James and Lorna Mack Endowed Chair in Bioengineering. In 2015, he joined the University of Idaho. Over the course of his academic career, Peng has been involved with research in drug/gene delivery using viral and nonviral vectors as well as ultrasonic device, developing phagocytosis-resistant perfluorocarbon-based oxygen carriers using PEGylated fluorosurfactant and CD47 ligand, photothermolysis of cancer cells using nanomaterials, and detection of antiviral agents using nanobiosensors.

Drug/gene delivery, Nano/Bio Technology